Publications
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine, First Faculty of Medicine
- Multiple sclerosis patient suitable for the treatment with ofatumumab2022 | Faculty of Medicine in Hradec Králové
- Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS2021 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine
- Treatment persistence to ocrelizumab and local experience2021 | Faculty of Medicine in Hradec Králové
- Profile of a patient treated with siponimod in routine clinical practice2021 | Faculty of Medicine in Hradec Králové
- Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis - current experience2021 | Faculty of Medicine in Hradec Králové
- Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase2020 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Multiple sclerosis: adherence to treatment2020 | Faculty of Medicine in Hradec Králové
- Long-term effect of immediate versus delayed treatment with fingolimod in young adult patients with RR-RS2020 | Faculty of Medicine in Hradec Králové
- Pharmacovigilance of novel treatments for multiple sclerosis2019 | Faculty of Medicine in Hradec Králové
Loading network view...
